In accordance to this observation, TRIM28 reduction did not change the percentage of CSCs characterized by the CD44+CD24−/low phenotype in vitro in the tested breast cancer cell lines (Figure 2H and Supplementary Figure S2E). This evidence concerns the gene CD24 and breast carcinoma.